Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report)'s share price traded down 6.5% on Tuesday . The stock traded as low as $5.98 and last traded at $6.04. 669,078 shares were traded during mid-day trading, a decline of 55% from the average session volume of 1,503,285 shares. The stock had previously closed at $6.46.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. Piper Sandler boosted their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th.
View Our Latest Research Report on ADPT
Adaptive Biotechnologies Stock Performance
The company has a market capitalization of $895.80 million, a P/E ratio of -4.53 and a beta of 1.47. The firm's fifty day moving average is $6.05 and its 200-day moving average is $5.06.
Institutional Investors Weigh In On Adaptive Biotechnologies
Several hedge funds and other institutional investors have recently made changes to their positions in ADPT. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at approximately $34,000. MQS Management LLC bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at approximately $36,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at approximately $49,000. Finally, Townsquare Capital LLC bought a new stake in Adaptive Biotechnologies during the 3rd quarter worth approximately $56,000. 99.17% of the stock is owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Further Reading
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
